MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Protagonist Therapeutics Inc

Avatud

SektorTervishoid

43.96 -3.21

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

43.34

Max

45.71

Põhinäitajad

By Trading Economics

Sissetulek

165M

132M

Müük

166M

171M

P/E

Sektori keskmine

10.827

57.333

Aktsiakasum

1.98

Kasumimarginaal

77.166

Töötajad

126

EBITDA

168M

127M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+51.17% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

5. mai 2025

Turustatistika

By TradingEconomics

Turukapital

631M

2.8B

Eelmine avamishind

47.17

Eelmine sulgemishind

43.96

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Protagonist Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. märts 2025, 13:59 UTC

Suurimad hinnamuutused turgudel

Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra

Võrdlus sarnastega

Hinnamuutus

Protagonist Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

51.17% tõus

12 kuu keskmine prognoos

Keskmine 67.8 USD  51.17%

Kõrge 82 USD

Madal 38 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Protagonist Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

9

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

42.62 / 45.85Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.